Evaxion A/S announced on July 1, 2026, that it will present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop. The company is a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines.
